Expertise in
2
conditions

Dr. Erin K. Barr

Pediatric Hematology Oncology
4102 24th Street, Suite 205, 
Lubbock, TX 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
2
conditions
4102 24th Street, Suite 205, 
Lubbock, TX 

Overview

Erin Barr is a Pediatric Hematologist Oncology provider practicing medicine in Lubbock, Texas.

Dr. Barr is highly rated in 2 conditions, according to our data. Her clinical expertise encompasses Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, Histiocytosis, Reticulohistiocytoma, and Bone Marrow Aspiration.

She is actively involved in clinical research, co-authoring 6 peer reviewed articles and participating in 18 clinical trials. Dr. Barr is currently accepting new patients.

Specialties

Pediatric Hematology Oncology

Licenses

Pediatrics in TX

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Baylor Scott & White Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
Cigna
  • EPO
  • HMO
  • PPO
FirstCare
  • HMO
Friday Health

Accepted plan types not found. Please verify directly with the provider.

Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
Superior Health Plan
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

4102 24th Street, Suite 205, Lubbock, TX 79410

Additional Areas of Focus

Dr. Barr has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
A Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Radiation, Drug, Biological, Other
Study Drugs: Cyclophosphamide, Dactinomycin, Irinotecan hydrochloride, Temsirolimus, Vincristine sulfate, Vinorelbine
Study Phase: Phase 3
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
NCI COVID-19 in Cancer Patients Study (NCCAPS): A Longitudinal Natural History Study
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Procedure
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Other, Procedure
Study Drugs: Carboplatin, Cisplatin, Doxorubicin, Etoposide, Fluorouracil, Gemcitabine, Irinotecan, Oxaliplatin, Sorafenib, Vincristine Sulfate
Study Phase: Phase 3
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients With Non-High-Risk Neuroblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 25, 2026
Intervention Type: Drug, Procedure, Other
Study Drugs: Carboplatin, Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide
Study Phase: Phase 3
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 24, 2026
Intervention Type: Biological, Drug, Procedure, Radiation
Study Drugs: Cyclophosphamide, Doxorubicin Hydrochloride, Etoposide Phosphate, Filgrastim, Nivolumab, Pegfilgrastim, Prednisolone, Prednisone, Rituximab, Rituximab+Hyaluronidase Human, Vincristine Sulfate
Study Phase: Phase 3
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Procedure, Other, Biological
Study Drugs: Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Dexrazoxane Hydrochloride, Doxorubicin, Etoposide, Filgrastim, Ifosfamide, Imatinib Mesylate, Leucovorin Calcium, Mercaptopurine, Methotrexate, Methylprednisolone, Pegaspargase, Prednisolone, Hydrocortisone, Thioguanine, Vincristine Sulfate
Study Phase: Phase 3
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: August 19, 2026
Intervention Type: Drug, Other
Study Drugs: Asparaginase, Erwinia Asparaginase, Cytarabine, Daunorubicin, Etoposide, Mitoxantrone, Thioguanine
Study Phase: Phase 3
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)
Enrollment Status: Active_not_recruiting
Publish Date: August 13, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Carboplatin, Selumetinib Sulfate, Vincristine Sulfate
Study Phase: Phase 3
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Drug, Biological, Procedure, Other, Radiation
Study Drugs: Brentuximab, Dacarbazine, Doxorubicin, Filgrastim, Nivolumab, Pegfilgrastim, Vinblastine
Study Phase: Phase 3
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-292 in Patients With Tumors Harboring RET Gene Alterations
Enrollment Status: Active_not_recruiting
Publish Date: August 03, 2026
Intervention Type: Procedure, Drug
Study Drug: Selpercatinib
Study Phase: Phase 2
View 9 Less Clinical Trials

6 Total Publications

Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Long-term follow-up of patients with intermediate-risk neuroblastoma treated with response- and biology-based therapy: A report from the Children's Oncology Group study ANBL0531.
Journal: Pediatric blood & cancer
Published: January 30, 2024
Similar Doctors
Expertise in
2
conditions
Dr. Kishor M. Bhende
Pediatric Hematology Oncology
Expertise in
2
conditions
Dr. Kishor M. Bhende
Pediatric Hematology Oncology
Referral may be required
Before you request
4102 24th Street, Suite 205, 
Anchorage, TX 
 (0.7 miles away)
806-725-4840
Languages Spoken:
English, Arabic, Cantonese, Hindi
See accepted insurances
Accepting New Patients
Offers Telehealth

Kishor Bhende is a Pediatric Hematologist Oncology provider practicing medicine in Anchorage, Texas. Dr. Bhende is highly rated in 2 conditions, according to our data. His clinical expertise encompasses Rhabdoid Tumor, Ewing Sarcoma, Neuroblastoma, Reticulohistiocytoma, and Bone Marrow Aspiration. Dr. Bhende is currently accepting new patients.

Expertise in
0
conditions
Dr. Mohamad M. Al-Rahawan
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Mohamad M. Al-Rahawan
Pediatric Hematology Oncology
Referral may be required
Before you request
4102 24th Street, Suite 205, 
Lubbock, TX 
 (0.1 miles away)
806-725-4840
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Mohamad Al-Rahawan is a Pediatric Hematologist Oncology provider practicing medicine in Lubbock, Texas. His clinical expertise encompasses Pineoblastoma, Acute Lymphoblastic Leukemia (ALL), Hereditary Spherocytosis, and Immune Thrombocytopenic Purpura (ITP). Dr. Al-Rahawan is currently accepting new patients.

Expertise in
0
conditions
Dr. Chibuzo C. O'suoji
Pediatric Hematology Oncology
Expertise in
0
conditions
Dr. Chibuzo C. O'suoji
Pediatric Hematology Oncology
Referral may be required
Before you request
4102 24th Street, Suite 205, 
Lubbock, TX 
 (0.1 miles away)
806-725-4840
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Chibuzo O'suoji is a Pediatric Hematologist Oncology provider practicing medicine in Lubbock, Texas. Her clinical expertise encompasses Acute Lymphoblastic Leukemia (ALL), Immune Thrombocytopenic Purpura (ITP), and Neurofibromatosis Type 1 (NF1). Dr. O'suoji is currently accepting new patients.

Frequently Asked Questions about Dr. Erin K. Barr

How do I make an appointment with Dr. Erin K. Barr?

You can book an appointment with Dr. Erin K. Barr by calling their office at 806-725-4840. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Erin K. Barr a top-rated expert for Neuroblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Erin K. Barr is classified as an Advanced expert for Neuroblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Erin K. Barr specialize in?

While Dr. Erin K. Barr is a Pediatric Hematology Oncology, they have specific expertise in Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, and Histiocytosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Pediatric Hematology Oncology.

Does Dr. Erin K. Barr participate in research or clinical trials?

Yes. Dr. Erin K. Barr has published 6 articles and abstracts on conditions like Neuroblastoma. You can view a list of Dr. Erin K. Barr's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Erin K. Barr accept my insurance?

Dr. Erin K. Barr accepts most major insurance plans, including Anthem BCBS and Baylor Scott & White Health. We recommend calling the office directly at 806-725-4840 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Barr's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile